Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients
Authors' conclusion
We identify two peptide antibodies, anti-SNRK and anti-HUWE1 antibodies, as pretreatment predictors of good therapeutic response to tofacitinib in RA patients.
Study context
- Population
- Rheumatoid arthritis (RA) patients who had received 24-week tofacitinib therapy12 discovery, 94 replication
- Participants
- 106 patients
- Comparison
- Anti-SNRK antibody vs anti-HUWE1 antibody for predicting good response to tofacitinib
- Outcome
- Good response to tofacitinib (EULAR response criteria, DAS28-ESR)
- Follow-up
- 24 weeks
Methodological detailsdiscovery and replication stages, phage immunoprecipitation sequencing (PhIP-Seq) discovery, enzyme-linked immunosorbent assay (ELISA) validation
- Discovery and replication stages
- PhIP-Seq discovery
- ELISA validation
Performance
As reported in the abstract
Prediction of good response (ELISA validation cohort)
| Test or model | Cut-off | AUC | Specificity | Sensitivity | P |
|---|---|---|---|---|---|
| Anti-SNRK antibody | 0.381 | 0.823 | 80.6% | 78.1% | P = 3.01E-07 |
| Anti-HUWE1 antibody | 0.362 | 0.740 | 74.2% | 62.5% | P < 0.001 |
Cut-off
Anti-SNRK antibody0.381
Anti-HUWE1 antibody0.362
AUC
Anti-SNRK antibody0.823
Anti-HUWE1 antibody0.740
Specificity
Anti-SNRK antibody80.6%
Anti-HUWE1 antibody74.2%
Sensitivity
Anti-SNRK antibody78.1%
Anti-HUWE1 antibody62.5%
P
Anti-SNRK antibodyP = 3.01E-07
Anti-HUWE1 antibodyP < 0.001
Further findings
Correlation of anti-SNRK and anti-HUWE1 antibodies with plasma caspase-1 and IL-18
- Positively correlated with caspase-1 and IL-18 levels (both P < 0.05)
Multivariate logistic regression
- Anti-SNRK antibody a significant predictor of good therapeutic response
Anti-SNRK antibody levels after tofacitinib
- Significantly declined in good responders, but not in non-good responders
Original publication
Anti-peptide antibodies, anti-SNRK and anti-HUWE1 antibodies as potential predictors of good response to tofacitinib therapy in rheumatoid arthritis patients. Rheumatology (Oxford). Published 24 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →